Please upgrade your browser

We built this website using the latest browser technologies to deliver the very best experience.

This makes the site run faster and easier to use. Unfortunately, your browser is out of date and will not support some of these technologies.

We recommend that you use a modern browser such as Google Chrome or Microsoft Edge to view this website.

Download Microsoft EdgeDownload Microsoft Edge
Press release

Sensyne Health appoints Chief Operating Officer

September 10, 2020

Oxford, U.K. 10 September 2020: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the UK Clinical AI company, announces that it has appointed Michael Macdonnell to its senior management team as Chief Operating Officer (COO) reporting to the CEO Lord Drayson. Michael will join Sensyne with effect from 28 September 2020.

Michael is currently Director of Global Deployment at Google Health, which he joined from Google DeepMind. Prior to joining Google, Michael was National Director of System Transformation and Director of Strategy at NHS England where he oversaw the delivery of key strategic initiatives including the NHS Five Year Forward View and the development of integrated care systems.

Previously, Michael has held roles at Accenture, the Centre for Health Policy, Imperial College London and as an advisor at the Prime Minister’s Delivery Unit.

Michael remains an honorary fellow at the Institute of Global Health Innovation, Imperial College London, and is a Policy Fellow at the Centre for Science and Policy, University of Cambridge.

Lord (Paul) Drayson PhD, CEO of Sensyne Health, said:

“Michael brings deep healthcare expertise and a strong track-record of driving healthcare improvements through the application of advanced technology. His experience of applying artificial intelligence to real-world research and clinical practice, in collaboration with both NHS and US-based healthcare providers, will be crucial in helping Sensyne to grow to its next stage of development. Importantly, he also strongly values social purpose, which matches Sensyne’s unique business model and ethical approach to the use of clinical AI.”

Michael Macdonnell, said:

“Sensyne is an exceptional opportunity: a company that combines social impact with the capabilities to effect real change in how healthcare is delivered. Data insights and digital therapeutics could bring about an era of proactive or anticipatory care and disrupt a model of medicine too often based on the average patient. By working and sharing value with our healthcare partners, we can build a game-changing portfolio of technologies that will improve care for patients in the NHS and around the world.”

Press release

Sensyne Health appoints Chief Operating Officer

September 10, 2020

Oxford, U.K. 10 September 2020: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the UK Clinical AI company, announces that it has appointed Michael Macdonnell to its senior management team as Chief Operating Officer (COO) reporting to the CEO Lord Drayson. Michael will join Sensyne with effect from 28 September 2020.

Michael is currently Director of Global Deployment at Google Health, which he joined from Google DeepMind. Prior to joining Google, Michael was National Director of System Transformation and Director of Strategy at NHS England where he oversaw the delivery of key strategic initiatives including the NHS Five Year Forward View and the development of integrated care systems.

Previously, Michael has held roles at Accenture, the Centre for Health Policy, Imperial College London and as an advisor at the Prime Minister’s Delivery Unit.

Michael remains an honorary fellow at the Institute of Global Health Innovation, Imperial College London, and is a Policy Fellow at the Centre for Science and Policy, University of Cambridge.

Lord (Paul) Drayson PhD, CEO of Sensyne Health, said:

“Michael brings deep healthcare expertise and a strong track-record of driving healthcare improvements through the application of advanced technology. His experience of applying artificial intelligence to real-world research and clinical practice, in collaboration with both NHS and US-based healthcare providers, will be crucial in helping Sensyne to grow to its next stage of development. Importantly, he also strongly values social purpose, which matches Sensyne’s unique business model and ethical approach to the use of clinical AI.”

Michael Macdonnell, said:

“Sensyne is an exceptional opportunity: a company that combines social impact with the capabilities to effect real change in how healthcare is delivered. Data insights and digital therapeutics could bring about an era of proactive or anticipatory care and disrupt a model of medicine too often based on the average patient. By working and sharing value with our healthcare partners, we can build a game-changing portfolio of technologies that will improve care for patients in the NHS and around the world.”

Press release

Sensyne Health appoints Chief Operating Officer

Sensyne Health appoints Chief Operating Officer

September 10, 2020

Oxford, U.K. 10 September 2020: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the UK Clinical AI company, announces that it has appointed Michael Macdonnell to its senior management team as Chief Operating Officer (COO) reporting to the CEO Lord Drayson. Michael will join Sensyne with effect from 28 September 2020.

Michael is currently Director of Global Deployment at Google Health, which he joined from Google DeepMind. Prior to joining Google, Michael was National Director of System Transformation and Director of Strategy at NHS England where he oversaw the delivery of key strategic initiatives including the NHS Five Year Forward View and the development of integrated care systems.

Previously, Michael has held roles at Accenture, the Centre for Health Policy, Imperial College London and as an advisor at the Prime Minister’s Delivery Unit.

Michael remains an honorary fellow at the Institute of Global Health Innovation, Imperial College London, and is a Policy Fellow at the Centre for Science and Policy, University of Cambridge.

Lord (Paul) Drayson PhD, CEO of Sensyne Health, said:

“Michael brings deep healthcare expertise and a strong track-record of driving healthcare improvements through the application of advanced technology. His experience of applying artificial intelligence to real-world research and clinical practice, in collaboration with both NHS and US-based healthcare providers, will be crucial in helping Sensyne to grow to its next stage of development. Importantly, he also strongly values social purpose, which matches Sensyne’s unique business model and ethical approach to the use of clinical AI.”

Michael Macdonnell, said:

“Sensyne is an exceptional opportunity: a company that combines social impact with the capabilities to effect real change in how healthcare is delivered. Data insights and digital therapeutics could bring about an era of proactive or anticipatory care and disrupt a model of medicine too often based on the average patient. By working and sharing value with our healthcare partners, we can build a game-changing portfolio of technologies that will improve care for patients in the NHS and around the world.”

Press release

Sensyne Health appoints Chief Operating Officer

Sensyne Health appoints Chief Operating Officer

Oxford, U.K. 10 September 2020: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the UK Clinical AI company, announces that it has appointed Michael Macdonnell to its senior management team as Chief Operating Officer (COO) reporting to the CEO Lord Drayson. Michael will join Sensyne with effect from 28 September 2020.

Michael is currently Director of Global Deployment at Google Health, which he joined from Google DeepMind. Prior to joining Google, Michael was National Director of System Transformation and Director of Strategy at NHS England where he oversaw the delivery of key strategic initiatives including the NHS Five Year Forward View and the development of integrated care systems.

Previously, Michael has held roles at Accenture, the Centre for Health Policy, Imperial College London and as an advisor at the Prime Minister’s Delivery Unit.

Michael remains an honorary fellow at the Institute of Global Health Innovation, Imperial College London, and is a Policy Fellow at the Centre for Science and Policy, University of Cambridge.

Lord (Paul) Drayson PhD, CEO of Sensyne Health, said:

“Michael brings deep healthcare expertise and a strong track-record of driving healthcare improvements through the application of advanced technology. His experience of applying artificial intelligence to real-world research and clinical practice, in collaboration with both NHS and US-based healthcare providers, will be crucial in helping Sensyne to grow to its next stage of development. Importantly, he also strongly values social purpose, which matches Sensyne’s unique business model and ethical approach to the use of clinical AI.”

Michael Macdonnell, said:

“Sensyne is an exceptional opportunity: a company that combines social impact with the capabilities to effect real change in how healthcare is delivered. Data insights and digital therapeutics could bring about an era of proactive or anticipatory care and disrupt a model of medicine too often based on the average patient. By working and sharing value with our healthcare partners, we can build a game-changing portfolio of technologies that will improve care for patients in the NHS and around the world.”

Arrange to meet us
Press release

Sensyne Health appoints Chief Operating Officer

September 10, 2020

Oxford, U.K. 10 September 2020: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the UK Clinical AI company, announces that it has appointed Michael Macdonnell to its senior management team as Chief Operating Officer (COO) reporting to the CEO Lord Drayson. Michael will join Sensyne with effect from 28 September 2020.

Michael is currently Director of Global Deployment at Google Health, which he joined from Google DeepMind. Prior to joining Google, Michael was National Director of System Transformation and Director of Strategy at NHS England where he oversaw the delivery of key strategic initiatives including the NHS Five Year Forward View and the development of integrated care systems.

Previously, Michael has held roles at Accenture, the Centre for Health Policy, Imperial College London and as an advisor at the Prime Minister’s Delivery Unit.

Michael remains an honorary fellow at the Institute of Global Health Innovation, Imperial College London, and is a Policy Fellow at the Centre for Science and Policy, University of Cambridge.

Lord (Paul) Drayson PhD, CEO of Sensyne Health, said:

“Michael brings deep healthcare expertise and a strong track-record of driving healthcare improvements through the application of advanced technology. His experience of applying artificial intelligence to real-world research and clinical practice, in collaboration with both NHS and US-based healthcare providers, will be crucial in helping Sensyne to grow to its next stage of development. Importantly, he also strongly values social purpose, which matches Sensyne’s unique business model and ethical approach to the use of clinical AI.”

Michael Macdonnell, said:

“Sensyne is an exceptional opportunity: a company that combines social impact with the capabilities to effect real change in how healthcare is delivered. Data insights and digital therapeutics could bring about an era of proactive or anticipatory care and disrupt a model of medicine too often based on the average patient. By working and sharing value with our healthcare partners, we can build a game-changing portfolio of technologies that will improve care for patients in the NHS and around the world.”